עמוד 1 מ 56 תוצאות
This application is related to U.S. Disclosure Document No. 520,804 that has the Filing Date of Oct. 29, 2002 that is entitled "Additional Methods of Using the Inhalers for Sports Performance, to Enhance memory, To Prevent, Treat or Cure PMS, Hot Flashes, and Night Sweats, to Treat or Reduce Stress,
BACKGROUND OF THE INVENTION
One of the inventors has poor respiratory health, has had repeated bouts with pneumonia, colds, flu, asthma, and has been recently diagnosed with the initial stages of emphysema--despite all that modern medicine has had to offer. This first inventor also comes from a
FIELD OF THE INVENTION
The present invention relates to the use of centrally acting NK.sub.1 antagonists to treat nausea and vomiting, particular nausea and vomiting induced by highly emetogenic chemotherapy, and to the treatment of such nausea and vomiting over multiple consecutive days. The
FIELD OF THE INVENTION
The present invention relates to the use of centrally acting NK.sub.1 antagonists to treat nausea and vomiting, particular nausea and vomiting induced by highly emetogenic chemotherapy, and to the treatment of such nausea and vomiting over multiple consecutive days. The
FIELD OF THE INVENTION
The present invention relates to the use of centrally acting NK.sub.1 antagonists to treat nausea and vomiting, particular nausea and vomiting induced by highly emetogenic chemotherapy, and to the treatment of such nausea and vomiting over multiple consecutive days. The
FIELD OF THE INVENTION
The present invention relates to the use of centrally acting NI.sub.1 antagonists to treat nausea and vomiting, particular nausea and vomiting induced by highly emetogenic chemotherapy, and to the treatment of such nausea and vomiting over multiple consecutive days. The
FIELD OF THE INVENTION
The present invention relates to the use of centrally acting NK.sub.1 antagonists to treat nausea and vomiting, particular nausea and vomiting induced by highly emetogenic chemotherapy, and to the treatment of such nausea and vomiting over multiple consecutive days. The
FIELD OF THE INVENTION
The present invention relates to the use of S-alkylisothiouronium derivatives, including, but not limited to, S-ethylisothiouronium diethylphosphate, for the prevention or treatment of headache, including but not limited to migraine, and for the prevention or treatment of
FIELD OF THE INVENTION
The present invention relates to the use of S-alkylisothiouronium derivatives, including, but not limited to, S-ethylisothiouronium diethylphosphate, for the prevention or treatment of headache, including but not limited to migraine, and for the prevention or treatment of
RELATED APPLICATIONS
This application is a U.S. National Phase application, filed under 35 U.S.C. .sctn. 371(c), of International Application No. PCT/GB2016/050998, filed on Apr. 11, 2016, which claims the benefit of and priority to United Kingdom Patent Application No. 1506116.1, filed on Apr. 10,
BACKGROUND OF THE INVENTION
This invention relates to novel compositions of matter containing optically pure R(+) ondansetron. These novel compositions have potent antiemetic activity and are useful in ameliorating the nausea and vomiting otherwise induced by cancer chemotherapeutic agents and
FIELD OF THE INVENTION
The present invention relates in general to methods for delivering therapeutic compounds across the blood-brain barrier of patients, and more particularly to the use of cannabinoids coupled to a chemotherapy agent for transport across the blood-brain barrier.
BACKGROUND OF THE
BACKGROUND OF THE INVENTION
The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol
BACKGROUND OF THE INVENTION
The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol
TECHNICAL FIELD
The present invention relates to NK.sub.1 receptor antagonist useful as medicaments.
More particularly, the present invention relates to NK.sub.1 receptor antagonist or pharmaceutically acceptable salts thereof which have substance P/neurokinin 1 (NK.sub.1) receptor antagonist